title: Inhibition of integrin-mediated platelet aggregation, fibrinogen-binding, and interactions with extracellular matrix by nonpeptidic mimetics of Arg-Gly-Asp.
abstract: The interaction of the activated platelet integrin, glycoprotein IIb-IIIa (GPIIb-IIIa) with fibrinogen and von-Willebrand factor (vWF) is essential for platelet aggregation. The minimal structure required for this integrin's binding to fibrinogen is the Arg-Gly-Asp (RGD) sequence. Inasmuch as normal level of GPIIb-IIIa-RGD interactions are required for maintaining hemostasis, elevated platelet aggregation can cause adverse pathological effects. We have previously reported that nonpeptidic mimetics of RGD, consisting of carboxylate and guanidinium groups of Asp and Arg divided by a linear 11-atom spacer, acquired a significant affinity for the GPIIb-IIIa integrin and inhibited platelet aggregation. The structural requirements for the interactions of the RGD sequence with GPIIb-IIIa and the inhibitory potential of a newly designed series of mimetics on platelet aggregation and interactions with extracellular matrix (ECM) were assayed herein. Adenosine-diphosphate (ADP)-induced platelet aggregation was inhibited in a dose-dependent manner by various RGD mimetics, with a maximal inhibition of 80-100% with an IC50 of 3 microM for the most potent inhibitor, NS-11, in which a six-membered ring was introduced into the spacer chain, which exceeded the IC50 attained with the original RGDS peptide. The inhibitory effect of the RGD mimetics was attributed to their specific interaction with the GPIIb-IIIa integrin, since these mimetics inhibited the binding of the PAC-1 mAb to GPIIb-IIIA. Furthermore, the binding of 125I-labeled fibrinogen to platelets was inhibited by the RGD surrogates in a dose-dependent and saturable manner. The RGD-mimetics also inhibited up to 70% the adhesion, aggregation, and deposition of platelets onto ECM.(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: National Hemophilia Center, Chaim Sheba Medical Center, Tel-Aviv, Israel.
authors.forename: D
authors.initials: D
authors.lastname: Varon
authors.forename: O
authors.initials: O
authors.lastname: Lider
authors.forename: R
authors.initials: R
authors.lastname: Dardik
authors.forename: B
authors.initials: B
authors.lastname: Shenkman
authors.forename: R
authors.initials: R
authors.lastname: Alon
authors.forename: R
authors.initials: R
authors.lastname: Hershkoviz
authors.forename: G
authors.initials: G
authors.lastname: Kapustina
authors.forename: N
authors.initials: N
authors.lastname: Savion
authors.forename: U
authors.initials: U
authors.lastname: Martinowitz
authors.forename: N
authors.initials: N
authors.lastname: Greenspoon
mesh_terms: D000595:Amino Acid Sequence; D054641:Dual Specificity Phosphatase 2; D005109:Extracellular Matrix / Q000187:drug effects*; D005340:Fibrinogen / Q000378:metabolism*; D006801:Humans; D016023:Integrins / Q000037:antagonists & inhibitors*; D008969:Molecular Sequence Data; D015394:Molecular Structure; D009842:Oligopeptides / Q000378:metabolism / Q000494:pharmacology*; D010975:Platelet Aggregation Inhibitors / Q000378:metabolism / Q000494:pharmacology*; D010980:Platelet Membrane Glycoproteins / Q000378:metabolism; D011485:Protein Binding; D054648:Protein Phosphatase 2; D017027:Protein Tyrosine Phosphatases / Q000097:blood; D011971:Receptors, Immunologic
chemical_list: D016023:Integrins; D009842:Oligopeptides; D010975:Platelet Aggregation Inhibitors; D010980:Platelet Membrane Glycoproteins; D011971:Receptors, Immunologic; C047981:arginyl-glycyl-aspartic acid; D005340:Fibrinogen; D054648:Protein Phosphatase 2; C517032:DUSP2 protein, human; D054641:Dual Specificity Phosphatase 2; D017027:Protein Tyrosine Phosphatases